Cancer

Cancer is no longer, for most patients, an acute disease with a short timeline. It has become a chronic condition — often survived, frequently returning, and almost always leaving durable effects on the body, the mind, and the family. The five-year relative survival rate for all cancers combined reached a milestone 70% in the American Cancer Society's 2026 statistics report — up from only 49% in the mid- 1970s. Roughly 18.6 million Americans are living with a history of cancer today; by 2040, an estimated 73% of survivors will be over the age of 65. This shift — from cancer as a mortality event to cancer as a survivable, recurrent, chronic condition — has created an entirely new dependency landscape. The person who survives lymphoma at 62 may live 20 more years, but with cognitive changes from chemotherapy, cardiac dysfunction from anthracyclines, peripheral neuropathy that alters gait and balance, secondary malignancies from radiation, and — often — recurrent surveillance anxiety that never fully resolves. For families, the diagnosis and initial treatment are only the first phase of a long caregiving arc. In 2026 in the United States, approximately 2,114,850 new cancer diagnoses will occur (about 5,800 each day) and 626,140 people will die from the disease. Cancer is heavily age-associated: 88% of diagnoses are in people 50 or older, and 59% in people 65 or older. Lung cancer will cause more deaths in 2026 than second-ranking colorectal and third-ranking pancreatic cancer combined. Yet mortality rates continue to decline — the overall cancer death rate has dropped 34% since its 1991 peak, averting an estimated 4.8 million deaths.

Key Facts at a Glance

• Prevalence: ~18.6 million cancer survivors alive in the U.S.; ~2.1 million new diagnoses expected in 2026; ~626,000 deaths. Lifetime risk of cancer is 1 in 3 for both men and women.
• Age concentration: 88% of cancer diagnoses occur in people age 50 or older; 59% in people 65 or older. Cancer incidence rises steeply with age.
• Five-year survival: Reached 70% for the first time (diagnoses 2015-2021). Ranges from 98% for thyroid and prostate to 13% for pancreatic. Distant-stage lung cancer survival has risen from 2% to 10% since the mid-1990s.
• Late effects prevalence: Chemotherapy-induced peripheral neuropathy affects 40-70% of patients receiving neurotoxic agents; cancer-related cognitive impairment ("chemo brain") is reported in up to 40% of survivors, often persisting for years.
• The 2026 pipeline is extraordinary: Over 120 immune checkpoint inhibitor approvals; CAR-T cell therapies expanding into earlier lines and solid tumors; antibody-drug conjugates transforming breast and lung cancer; bispecific antibodies as off-the-shelf alternatives to CAR-T.

Cancer is not one disease. It is more than 200 distinct conditions united only by a common mechanism — the uncontrolled proliferation of cells that have accumulated the genetic and epigenetic changes required to bypass normal growth controls. A stage 1 papillary thyroid cancer and a stage 4 pancreatic adenocarcinoma share almost nothing biologically, clinically, or prognostically. Treatment and outcome depend heavily on the tissue of origin, the molecular subtype, the stage at diagnosis, and increasingly the specific mutations driving the individual tumor.

The Scale of the Problem

The Most Common Cancers

Three cancers account for approximately half of all new diagnoses in each sex. In men: prostate, lung, and colorectal cancer represent 48% of diagnoses, with prostate alone accounting for nearly one third. In women: breast, lung, and colorectal cancer represent 50% of diagnoses, with breast alone accounting for nearly one third.

How Cancer Develops

Every cancer begins with a series of mutations in a single cell that give it advantages over its neighbors: the ability to divide without stopping, to ignore signals that should trigger cell death, to escape immune surveillance, to attract blood supply, and eventually to invade nearby tissues and spread through blood and lymphatic vessels to distant sites. This process — called carcinogenesis — typically takes years to decades. Most cancers diagnosed in older adults reflect exposures and DNA damage that began decades earlier.

Cancer Staging

Staging describes how far a cancer has spread at the time of diagnosis. The TNM system — Tumor size, Node involvement, Metastasis — is the international standard. Most cancers are then grouped into stages 0 through IV.

Molecular Classification — The Modern Revolution

For a growing number of cancers, the tissue of origin has become secondary to the molecular subtype. A HER2-positive breast cancer is treated differently than a triple-negative breast cancer. A lung cancer with an EGFR mutation is treated with a completely different first-line therapy than a lung cancer with a KRAS G12C mutation. A colon cancer with microsatellite instability responds to immunotherapy in ways that microsatellite-stable colon cancer usually does not. Every newly diagnosed patient with metastatic or advanced-stage disease should have their tumor tested for actionable mutations — this testing has become one of the most consequential decisions early in the treatment plan.

Demographics and Disparities

• Native American people have the highest overall cancer mortality — death rates about 2x those of white people for kidney, liver, stomach, and cervical cancers
• Black Americans have higher mortality for many cancers including prostate, breast, colorectal, and multiple myeloma, driven by a combination of biological, social, and access-to-care factors
• Cancer death rates among Alaskan Native people are 2-3 times higher than any other U.S. ethnic group for colorectal cancer specifically
• Breast cancer incidence is rising in women younger than 50 — a troubling trend continuing through the 2026 report
• Colorectal cancer incidence is rising in adults younger than 50, prompting the U.S. screening age recommendation to drop from 50 to 45
• Prostate cancer diagnoses at advanced stages have increased since 2014, after decades of decline

Cancer creates dependency through three distinct channels: the acute treatment phase, the residual effects of treatment on survivors, and — for many — the recurrence, progression, or new primary cancer that arrives years later. Each channel produces different caregiving demands, and the family that plans for all three fares best.

3.1 Acute Treatment Burden

The initial treatment phase — surgery, chemotherapy, radiation, immunotherapy, or combinations — is intense and often overwhelming. Chemotherapy cycles run every 2-3 weeks for 4-8 months for most curative-intent regimens. Radiation is typically daily for 5-7 weeks. Immunotherapy infusions are every 2-6 weeks, often for a year or longer. Each modality carries characteristic side effects: nausea, fatigue, low blood counts (with risk of infection or bleeding), mouth sores, hair loss, skin reactions, and — in some regimens — hospitalization for fever or complications.

3.2 Fatigue — The Universal Symptom

Cancer-related fatigue is qualitatively different from ordinary tiredness. It is not relieved by rest. It affects roughly 80-90% of patients during active treatment and persists in 25-40% of survivors for years afterward. It is one of the most disabling symptoms in cancer survivorship — often a bigger driver of functional decline and loss of independence than the disease itself. Contributors include anemia, sleep disruption, inflammatory cytokines, muscle deconditioning, depression, and direct effects of chemotherapy and radiation.

3.3 Chemotherapy-Induced Peripheral Neuropathy (CIPN)

Roughly 40-70% of patients receiving neurotoxic chemotherapy agents (platinums, taxanes, vinca alkaloids, bortezomib, thalidomide/lenalidomide) develop peripheral neuropathy. The classic pattern is stocking-and-glove numbness, tingling, and pain in feet and hands. In many patients, CIPN persists for years after treatment ends — often permanently. Older adults are particularly vulnerable, and CIPN independently increases fall risk (nearly doubled in women with persistent CIPN), reduces gait stability, and impairs executive function.

3.4 Cancer-Related Cognitive Impairment ("Chemo Brain")

Cancer-related cognitive impairment — often called "chemo brain" or "chemo fog" by patients — is reported by up to 40% of survivors. Symptoms include word-finding difficulty, slower processing speed, executive dysfunction, and short-term memory problems. It is not restricted to chemotherapy: radiation to the brain, hormone therapies, immunotherapy, and cancer itself all contribute. In many patients, cognitive symptoms improve substantially in the first 1-2 years after treatment. In others, they persist indefinitely and — particularly in older adults — may accelerate the trajectory toward dementia.

3.5 Cardiotoxicity and Cardio-Oncology

Cancer treatments — especially anthracyclines (doxorubicin, epirubicin), HER2-directed therapies (trastuzumab, pertuzumab), radiation to the chest, and some newer immunotherapies — can damage the heart. Anthracycline-related heart failure may appear years or decades after treatment. Cancer survivors treated with anthracyclines and chest radiation have significantly elevated risk of heart failure, coronary artery disease, and valvular disease. Modern cardio-oncology programs screen at-risk survivors with periodic echocardiograms, aggressively control blood pressure and cholesterol, and use cardioprotective agents (ACE inhibitors, beta-blockers) at the first sign of subclinical dysfunction.

3.6 Secondary Malignancies

Cancer survivors have elevated risk of a second, unrelated cancer — both because of shared risk factors (smoking, obesity, radiation exposure) and because some cancer treatments are themselves carcinogenic. Approximately 1 in 6 new cancer diagnoses is in a patient with a prior cancer history. Radiation-induced secondary malignancies typically appear 10-25 years after treatment. Certain chemotherapies (alkylating agents, topoisomerase II inhibitors) increase the risk of therapy-related myelodysplastic syndrome or acute leukemia within 5-10 years.

3.7 Endocrine and Sexual Health

Cancer treatments frequently produce lasting endocrine effects: premature menopause from chemotherapy or ovarian suppression; androgen deprivation therapy for prostate cancer causing bone loss, sarcopenia, and cognitive changes; hormone therapy for breast cancer causing joint pain and osteoporosis; and radiation-induced thyroid or pituitary dysfunction. Sexual dysfunction — often unaddressed in follow-up visits — affects the majority of survivors of pelvic, breast, and hormonal cancers.

3.8 Psychological Distress and Fear of Recurrence

Depression, anxiety, and post-traumatic stress symptoms are common in cancer survivors. Approximately 25% of survivors report significant depressive symptoms in the first year post-treatment, with roughly 15% having persistent depression years later. Fear of recurrence is nearly universal and — in many patients — never fully resolves. Structured mental health treatment (cognitive-behavioral therapy, mindfulness-based interventions, medications when appropriate) has good evidence for cancer-related distress; every survivor should be screened for depression and anxiety at follow-up visits.

3.9 Recurrence and Metastatic Disease

For many common cancers, recurrence or progression to metastatic disease is a real possibility that surveillance is designed to catch. Metastatic breast cancer, prostate cancer, melanoma, colon cancer, and lung cancer are increasingly treated as chronic diseases — patients may live years with metastatic disease on modern therapies, cycling through lines of treatment. This creates a distinctive caregiving pattern: periods of stability alternating with treatment changes, imaging surveillance every few months, and gradual accumulation of treatment side effects over years.

Cancer diagnosis begins with either a screening test in an asymptomatic person or the evaluation of a symptom. From the abnormal screen or symptom to definitive diagnosis typically requires imaging, biopsy, and — in the modern era — molecular characterization. A treatment plan cannot responsibly be built without knowing the tissue of origin, the stage, and (for most cancers) the driving molecular alterations.

Screening — Cancers Where Early Detection Saves Lives

Symptoms That Warrant Prompt Evaluation

• Unexplained weight loss (more than 10 pounds without trying)
• New or changing lump or mass anywhere on the body
• Persistent cough or hoarseness lasting more than 3 weeks
• Change in bowel or bladder habits (new blood in stool or urine)
• Unusual bleeding — postmenopausal vaginal bleeding, bleeding between periods, or blood in stool or urine
• Difficulty swallowing or persistent indigestion
• Change in a mole (new, changing color, irregular borders, larger than 6 mm)
• Persistent fatigue not explained by other conditions
• Unexplained fever, night sweats, or bone pain

The Diagnostic Workup

Molecular and Genetic Testing

For almost all metastatic solid tumors and most hematologic malignancies, comprehensive molecular profiling is now standard of care. Testing may identify targetable alterations (EGFR, ALK, ROS1, BRAF, HER2, KRAS G12C, and many others), predictors of immunotherapy response (PD-L1 expression, tumor mutational burden, MSI status), or germline (inherited) mutations that have implications for family members. Ask, at diagnosis, whether comprehensive genomic profiling has been ordered and when results will return — treatment decisions should wait for these results when clinically feasible.

Geriatric Assessment for Older Adults

For adults 65 and older, a formal geriatric assessment before starting cancer treatment predicts outcomes better than age or ECOG performance status alone. The G-8 screening tool is a brief validated instrument that identifies patients who benefit from a full comprehensive geriatric assessment. Low G-8 scores independently predict poor overall and progression-free survival across digestive, lung, gynecologic, head/neck, hematologic, and prostate cancers. Geriatric assessment allows oncologists to modify treatment intensity, add supportive interventions, and set realistic expectations.

Cancer treatment has expanded from three original pillars — surgery, radiation, and chemotherapy — to include hormone therapy, targeted therapy, immunotherapy, cellular therapy, and antibody-drug conjugates. Most modern treatment plans combine several modalities. This section describes each in turn, with emphasis on what patients and families should know about the treatment experience and its late effects.

5.1 Surgery

For most solid tumors caught early, surgery is the primary curative treatment. Modern cancer surgery is increasingly minimally invasive — laparoscopic, robotic, or endoscopic techniques replace many traditional open procedures. Sentinel lymph node biopsy has largely replaced full axillary dissection in breast cancer. Nephron-sparing partial nephrectomy has largely replaced radical nephrectomy for small kidney tumors. These advances reduce recovery time, complications, and long-term functional loss. Late effects of cancer surgery include lymphedema (particularly after axillary or inguinal lymph node dissection), functional loss from resection of an organ, adhesions and bowel obstruction after abdominal surgery, urinary or bowel dysfunction after pelvic surgery, and — for major operations in older adults — postoperative delirium and functional decline.

5.2 Radiation Therapy

Radiation delivers ionizing energy to cancer cells to damage their DNA and kill them. Modern radiation is precise: intensity-modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), stereotactic body radiation therapy (SBRT), and proton beam therapy all allow high doses to be delivered to the tumor while sparing surrounding normal tissue. Typical curative-intent radiation is delivered daily for 5-7 weeks. Late effects depend heavily on the site treated: fibrosis and stiffness in the treated area, radiation pneumonitis or cardiac damage after chest radiation, dry mouth and dental problems after head-and-neck radiation, bowel or bladder dysfunction after pelvic radiation, cognitive effects after brain radiation, and — often years later — increased risk of secondary cancers within the radiation field.

5.3 Traditional Chemotherapy

Chemotherapy uses cytotoxic drugs to kill rapidly dividing cells — including cancer cells but also bone marrow, gastrointestinal lining, hair follicles, and immune cells. This is why the classic side effects (low blood counts, mouth sores, nausea, hair loss, fatigue) are so consistent across regimens. Combinations of 2-4 drugs are typically given in cycles every 2-3 weeks, allowing bone marrow to recover between doses. Common drug classes include:

• Alkylating agents (cyclophosphamide, ifosfamide, temozolomide) — DNA damage; risk of secondary leukemia years later
• Platinum compounds (cisplatin, carboplatin, oxaliplatin) — DNA damage; strongly associated with peripheral neuropathy and hearing loss
• Taxanes (paclitaxel, docetaxel, nab-paclitaxel) — disrupt microtubules; strongly neuropathic
• Anthracyclines (doxorubicin, epirubicin) — highly effective but cardiotoxic
• Antimetabolites (5-FU, capecitabine, methotrexate, gemcitabine, pemetrexed)
• Topoisomerase inhibitors (irinotecan, etoposide) — GI toxicity; secondary leukemia risk

5.4 Hormone Therapy

For cancers driven by hormones — breast, prostate, and endometrial in particular — hormone therapy is often central to treatment. In breast cancer: tamoxifen (blocks estrogen receptor) and aromatase inhibitors (anastrozole, letrozole, exemestane; block estrogen production) are given for 5-10 years after primary treatment for hormone-receptor-positive disease. In prostate cancer: androgen deprivation therapy (leuprolide, degarelix, and now oral agents including relugolix) suppresses testosterone; second-generation androgen receptor blockers (abiraterone, enzalutamide, apalutamide, darolutamide) provide additional suppression in advanced disease. Late effects of hormone therapy are substantial and often underappreciated: bone loss (osteoporosis, fracture), muscle loss (sarcopenia), joint pain (aromatase inhibitors), cognitive changes, fatigue, cardiovascular risk changes, sexual dysfunction, and mood effects. Every patient on prolonged hormone therapy should have baseline and periodic bone density scans, cardiovascular risk assessment, and monitoring of physical function.

5.5 Targeted Therapy

Targeted therapies are drugs designed to interfere with specific molecular abnormalities in cancer cells. Examples: HER2-directed therapies (trastuzumab, pertuzumab, T-DM1, trastuzumab deruxtecan) for HER2-positive breast and gastric cancers; EGFR inhibitors (osimertinib, gefitinib, erlotinib) for EGFR- mutant lung cancer; ALK inhibitors (alectinib, lorlatinib) for ALK-rearranged lung cancer; BRAF inhibitors (dabrafenib, vemurafenib, encorafenib) for BRAF-mutant melanoma; PARP inhibitors (olaparib, rucaparib, niraparib) for BRCA-mutant ovarian and breast cancers; and CDK4/6 inhibitors (palbociclib, abemaciclib, ribociclib) for hormone-receptor-positive breast cancer. Targeted therapies are typically better tolerated than traditional chemotherapy but bring their own side effects: skin rashes, diarrhea, hypertension, hypothyroidism, and — for some — cardiac toxicity or interstitial lung disease. Because targeted therapy depends on the presence of a specific molecular target, adequate molecular testing at diagnosis is essential.

5.6 Immunotherapy — Immune Checkpoint Inhibitors

Immune checkpoint inhibitors (ICIs) have transformed the treatment of many cancers over the past decade. They work by releasing the brakes on the patient's own immune system — allowing T cells to recognize and attack cancer cells. Approved agents include anti-PD-1 antibodies (pembrolizumab, nivolumab, cemiplimab, dostarlimab, retifanlimab), anti-PD-L1 antibodies (atezolizumab, durvalumab, avelumab), and anti-CTLA-4 antibody (ipilimumab). Combinations of two checkpoint inhibitors produce higher response rates and more toxicity. Immunotherapy is now first-line therapy for advanced melanoma, non-small cell lung cancer with high PD-L1 expression, kidney cancer, bladder cancer, some gastroesophageal cancers, hepatocellular carcinoma, and — as of March 2026 — perioperative treatment of resectable head and neck squamous cell carcinoma. Response rates in the most responsive cancers (melanoma, MSI-high tumors) exceed 40- 50%; durability of response is one of the most remarkable features — some patients remain in remission years after treatment ended.

5.7 Cellular Therapy — CAR-T Cells

Chimeric antigen receptor T-cell (CAR-T) therapy uses the patient's own T cells, genetically modified to express a receptor that targets a specific cancer antigen. FDA-approved CAR-T products currently target CD19 (for B-cell lymphomas and acute lymphoblastic leukemia) and BCMA (for multiple myeloma). Response rates in relapsed/refractory disease are unprecedented — 60-80% for many indications, with durable remissions in a substantial minority. The CAR-T experience is intense: cells are collected, sent to a manufacturing facility for 2-4 weeks, then re-infused after lymphodepleting chemotherapy. Cytokine release syndrome and neurotoxicity (immune effector cell-associated neurotoxicity syndrome, ICANS) are common in the first 1-2 weeks after infusion and require hospitalization and specialized management. As of 2026, CAR-T is expanding into earlier lines of therapy for the approved indications and being tested in solid tumors, though solid-tumor efficacy remains limited.

5.8 Bispecific Antibodies

Bispecific antibodies — engineered proteins that bind simultaneously to a cancer antigen and to a T cell — have emerged as off-the-shelf alternatives to CAR-T. FDA-approved agents include blinatumomab (CD19 x CD3 for B-cell ALL), teclistamab and elranatamab (BCMA x CD3 for multiple myeloma), talquetamab (GPRC5D x CD3 for multiple myeloma), epcoritamab and glofitamab (CD20 x CD3 for B-cell lymphomas), tarlatamab (DLL3 x CD3 for small cell lung cancer), and others. Unlike CAR-T, bispecifics are ready-to-use — no manufacturing wait, no lymphodepleting chemotherapy — but require ongoing infusions and share the cytokine release syndrome and neurotoxicity risks of CAR-T.

5.9 Antibody-Drug Conjugates (ADCs)

Antibody-drug conjugates combine a monoclonal antibody (targeting a cancer antigen) with a cytotoxic drug — using the antibody to deliver the drug specifically to cancer cells. The class has expanded dramatically. Notable agents in 2026 include trastuzumab deruxtecan (Enhertu) for HER2-positive and HER2-low breast cancer, HER2-mutant lung cancer, and HER2-positive gastric cancer; sacituzumab govitecan (Trodelvy) for triple-negative breast cancer and urothelial cancer; datopotamab deruxtecan (Datroway); enfortumab vedotin (Padcev) for urothelial cancer; and mirvetuximab soravtansine for folate receptor alpha-positive ovarian cancer. ADCs generally produce different toxicity profiles than either chemotherapy or targeted therapy — with interstitial lung disease being a particular concern for the deruxtecan-containing agents.

Survivorship — the period after primary cancer treatment — has been recognized as a distinct medical phase since a landmark 2005 Institute of Medicine report. Modern survivorship care rests on three pillars: surveillance for recurrence, screening for new primary cancers, and active management of late effects. Every patient completing primary cancer treatment should receive a written survivorship care plan summarizing the treatments received, the recommended follow-up schedule, and the specific late effects to watch for.

6.1 Fatigue Management

Cancer-related fatigue improves — but does not always resolve — after treatment ends. Interventions with the strongest evidence: exercise (aerobic and resistance training tailored to ability), cognitive-behavioral therapy, sleep optimization, and treatment of contributing conditions (anemia, hypothyroidism, depression, obstructive sleep apnea, medication side effects). Stimulant medications (methylphenidate, modafinil) have modest and inconsistent evidence. The single most effective intervention across trials is graded, structured exercise — even in patients who feel too tired to exercise.

6.2 Chemotherapy-Induced Peripheral Neuropathy

There is no proven neuroprotective agent for CIPN. During treatment, dose reduction or drug substitution is the main intervention when symptoms become severe. In survivors with persistent CIPN: duloxetine has the best evidence for pain relief; physical therapy and occupational therapy improve balance, gait, and safety of daily activities; and specific attention to fall prevention (home safety modifications, appropriate footwear, assistive devices when needed) is essential. Older adults with CIPN should be evaluated for driving safety.

6.3 Cognitive Rehabilitation

Cancer-related cognitive impairment responds partially to structured cognitive rehabilitation programs — brain training combined with strategy training, delivered in-person or (increasingly) via digital platforms. Aerobic exercise improves cognitive function in cancer survivors. Sleep optimization is important; both insomnia and sleep-disordered breathing are common in survivors and both worsen cognitive symptoms. Medications specifically for cancer-related cognitive impairment do not have consistent evidence and are not routinely recommended. Careful evaluation for depression and anxiety is important — both amplify cognitive symptoms.

6.4 Cardio-Oncology Follow-Up

Survivors treated with anthracyclines, HER2-directed therapy, chest radiation, or certain other agents should have long-term cardiac surveillance. Guidelines from the American Society of Clinical Oncology and European Society of Cardiology recommend baseline echocardiography before starting cardiotoxic therapy, periodic surveillance during treatment, and long-term follow-up for high-risk patients.

Aggressive management of traditional cardiovascular risk factors (blood pressure, cholesterol, diabetes, smoking, weight) is essential. Structured cardio-oncology clinics — increasingly available at academic cancer centers — coordinate this care.

6.5 Bone Health

Cancer survivors are at elevated risk of osteoporosis and fracture — from hormone therapies (aromatase inhibitors, androgen deprivation), chemotherapy-induced early menopause, glucocorticoid exposure, radiation, and reduced physical activity. Baseline bone density scan (DEXA) is recommended for survivors on prolonged hormone therapy, followed by periodic monitoring. Weight-bearing exercise, adequate calcium and vitamin D, and — when indicated — bisphosphonates or denosumab are all standard interventions.

6.6 Endocrine and Sexual Health

Screen periodically for thyroid dysfunction, adrenal insufficiency (particularly in immunotherapy recipients), diabetes (particularly after immunotherapy or steroid exposure), and hypogonadism. Sexual dysfunction — often unaddressed — affects the majority of survivors of pelvic, breast, and hormonal cancers. Specialized sexual health services are increasingly available at comprehensive cancer centers; ask specifically for a referral if this is a concern.

6.7 Psychosocial and Mental Health

Depression, anxiety, and post-traumatic stress affect a substantial minority of cancer survivors. Fear of recurrence is nearly universal. Structured mental health treatment — cognitive-behavioral therapy, mindfulness-based interventions, medications when appropriate — has good evidence for cancer-related distress. Peer support groups (in-person and virtual) reduce isolation. Every survivorship care plan should include mental health screening and a clear path to mental health care.

6.8 Surveillance for Recurrence

Surveillance schedules vary by cancer type and stage. Common elements include: history and physical exam every 3-6 months for the first 2-3 years, then annually; imaging as appropriate (chest CT for lung cancer, mammography for breast cancer, colonoscopy for colon cancer); and cancer-specific tumor markers when they have proven surveillance value (CEA for colon cancer, CA-125 for ovarian cancer, PSA for prostate cancer). Over-surveillance (unnecessary imaging, unnecessary blood tests) generates anxiety, false alarms, and complications without improving outcomes; the modern approach is targeted, evidence-based follow-up.

6.9 Screening for New Primary Cancers

Cancer survivors should continue standard age-appropriate screening for all other cancers — with adjustments for their specific history. A colon cancer survivor still needs mammography; a breast cancer survivor still needs colonoscopy. Survivors of radiation-treated cancers may need earlier or more intensive screening for radiation-field secondary cancers (chest wall radiation → earlier breast cancer screening; abdominal radiation → colorectal surveillance). Genetic testing at diagnosis may identify hereditary cancer syndromes that require lifelong specialized screening (Lynch syndrome, BRCA1/2, Li- Fraumeni).

Cancer therapeutics is arguably the most active area in all of medicine. Over 120 immune checkpoint inhibitor approvals as of 2026, an accelerating antibody-drug conjugate class, CAR-T expanding into earlier lines, bispecific antibodies as off-the-shelf T-cell engagers, and — on the horizon — CRISPR- edited and next-generation cellular therapies. This section highlights the most consequential developments in the current pipeline.

7.1 Immune Checkpoint Inhibitors — 2025-2026 Approvals

The 2025 Cancer Immunotherapy Report cataloged 155 total immunotherapy approvals globally: 120 checkpoint inhibitors, 19 cell and gene therapies, 13 bispecific antibodies, and a smaller number of other modalities. Notable 2025-2026 checkpoint approvals include:

7.2 Cell and Gene Therapy — CAR-T Expansion

CAR-T continues to expand from later lines into second-line and, increasingly, first-line therapy for approved indications. Second-line CAR-T is now standard of care in large B-cell lymphoma that relapses within 12 months of first-line therapy. BCMA-directed CAR-T for relapsed/refractory multiple myeloma produces overall response rates approaching 98% with stringent complete remission rates around 82%. Bispecific CAR-T (targeting two antigens simultaneously) is in early-phase testing to address the antigen-escape mechanisms that drive some CAR-T relapses. Cellular therapies are also expanding beyond hematologic malignancies. Tumor-infiltrating lymphocyte (TIL) therapy — lifileucel (Amtagvi) was FDA-approved in 2024 for advanced melanoma — represents the first cellular therapy for a solid tumor. CAR-T strategies for solid tumors (glioblastoma, prostate, gastric, pancreatic) are in Phase 1/2 development; efficacy has been modest to date.

7.3 Antibody-Drug Conjugates — The New Class

ADCs are the fastest-growing modality in oncology. Trastuzumab deruxtecan (Enhertu) — now approved for HER2-positive breast cancer (multiple lines), HER2-low breast cancer, HER2-mutant NSCLC, and HER2-positive gastric cancer — has shown transformative benefit in DESTINY trials. Datopotamab deruxtecan (Datroway) received FDA approval in January 2025 for previously treated HR-positive/HER2- negative metastatic breast cancer based on the TROPION-Breast01 trial. Additional ADCs approved or in advanced development in 2026:

• Sacituzumab govitecan (Trodelvy) — TROP-2-directed; triple-negative breast cancer, urothelial cancer, HR+/HER2- breast cancer
• Enfortumab vedotin (Padcev) — nectin-4-directed; combined with pembrolizumab as first-line for advanced urothelial cancer
• Mirvetuximab soravtansine (Elahere) — folate receptor alpha; platinum-resistant ovarian cancer
• Multiple next-generation deruxtecan ADCs — targeting HER3, TROP-2, and other antigens; some in registration-stage trials

7.4 Bispecific T-Cell Engagers

Bispecifics have moved into standard-of-care for several indications and are actively being tested in earlier lines. Teclistamab, elranatamab, and talquetamab all provide off-the-shelf alternatives to BCMA CAR-T for relapsed/refractory multiple myeloma. Epcoritamab and glofitamab are approved for relapsed/refractory diffuse large B-cell lymphoma. Tarlatamab (DLL3-targeted) received accelerated approval for small cell lung cancer — a disease with few effective options for decades — based on responses in the DeLLphi trials. Solid-tumor bispecifics targeting PSMA (prostate cancer), CEA (colorectal), and other antigens are in Phase 1/2 development.

7.5 Precision Oncology and Tumor-Agnostic Approvals

A growing number of drugs are now approved not by cancer site but by molecular biomarker — treatment is chosen based on the mutation rather than the tissue of origin. Pembrolizumab is approved for any solid tumor with high microsatellite instability (MSI-H) or high tumor mutational burden (TMB- H). Larotrectinib and entrectinib are approved for any solid tumor with NTRK gene fusions. Selpercatinib is approved for any solid tumor with RET fusions. Trastuzumab deruxtecan crosses the tumor-agnostic line in a slightly different way — approved for HER2-positive solid tumors regardless of tissue in some settings. Comprehensive molecular profiling at diagnosis is the gateway to identifying these opportunities.

7.6 Early-Detection Blood Tests

Multi-cancer early detection (MCED) blood tests — designed to screen for many cancers simultaneously by analyzing circulating tumor DNA — are undergoing large prospective trials. The Galleri test (GRAIL) and similar tests have been available commercially but are not yet endorsed by the U.S. Preventive Services Task Force or major cancer societies for average-risk screening. Ongoing trials (NHS-Galleri in the UK, PATHFINDER in the U.S., and others) will inform whether these tests reduce cancer mortality. Discuss with an oncologist before pursuing outside a clinical trial.

7.7 Cancer Vaccines

Therapeutic cancer vaccines — designed to train the immune system to attack cancer cells — remain an area of active development. Personalized mRNA neoantigen vaccines (combined with checkpoint inhibitors) have shown promising Phase 2 results in melanoma and pancreatic cancer. Off-the-shelf tumor-associated antigen vaccines have had a long history of disappointing trials but continue to be developed for specific indications. Prophylactic cancer vaccines — HPV vaccine (preventing cervical, anal, head/neck cancers) and hepatitis B vaccine (preventing hepatocellular carcinoma) — remain among the most consequential cancer prevention interventions available.

Cancer caregiving is intense and long. Unlike diseases with predictable trajectories, cancer caregiving often involves discrete phases — acute treatment, remission with surveillance, possible recurrence, possible cellular or targeted therapy, and (for many) end-of-life care — each with different demands. The family that plans for the arc, not just the current phase, fares best.

The Practical Load

• Transportation — infusions and radiation sessions during active treatment (potentially 20+ trips), imaging and lab visits, specialty consultations, emergency evaluations for fever or side effects
• Medication management — many oncology patients take 10-20 daily medications; oral chemotherapy adherence is complex and safety-critical
• Side effect monitoring — fever during neutropenia, dehydration during nausea/vomiting or diarrhea, signs of blood clots, immune-related adverse events (especially skin, gut, thyroid, lung, endocrine)
• Nutrition support — appetite loss and taste changes are common; specialized nutrition (small frequent meals, protein-rich foods, sometimes tube feeding) is often needed
• Emotional support — cancer diagnosis is life-changing; anxiety, depression, and existential distress affect most patients and families
• Care coordination — modern cancer treatment involves surgery, medical oncology, radiation oncology, palliative care, primary care, and multiple specialists; someone in the family typically becomes the informal care coordinator
• Advocacy — asking questions, tracking treatment plans, ensuring molecular testing has been done, exploring clinical trials, seeking second opinions when appropriate

Caregiver Burnout

Approximately 40-50% of family caregivers of cancer patients report significant emotional distress. Predictors include high caregiving hours per week, coexisting cognitive impairment in the patient, prolonged treatment duration, and lack of respite. Depression rates in cancer caregivers exceed general population rates. Physical health of caregivers deteriorates measurably over the years of caregiving — a well-documented phenomenon that hospitals and cancer centers increasingly try to address through explicit caregiver programs.

Palliative Care Throughout the Cancer Journey

Palliative care is not the same as hospice. Palliative care is expert symptom management and quality-of-life support for patients with serious illness — at any point in the disease course, including alongside curative-intent treatment. For cancer patients, palliative care teams provide expert management of pain, nausea, fatigue, anxiety, depression, dyspnea, and the many symptom clusters cancer produces. Multiple randomized trials have shown that early palliative care alongside standard cancer care improves quality of life, reduces depression, and — in some studies — extends survival. Ask for a palliative care consultation at any of these points: at diagnosis of any advanced or metastatic cancer, when symptoms are not well-controlled, when treatment decisions become complex, when the patient or family is struggling emotionally, or at any hospitalization. Palliative care is available at essentially all comprehensive cancer centers and most community hospitals; if it is not offered, ask for it.

Hospice Care

Hospice is the intensive palliative care model for patients in the final phase of a terminal illness — typically the last six months of life. Hospice care is provided at home, in a nursing facility, or in a dedicated hospice residence. It focuses entirely on comfort, symptom control, and family support; disease-directed treatment (chemotherapy, radiation with curative intent) is stopped, though palliative treatments to control symptoms continue. Referral to hospice is often too late — the median hospice stay for cancer patients in the U.S. is less than 3 weeks, meaning many families receive only a small fraction of the support the hospice model is designed to provide. Discussing hospice earlier — while the patient can still participate in decisions — is one of the most consistent recommendations from palliative care research.

Advance Directives

Every adult with cancer benefits from a completed advance directive and a durable power of attorney for health care. For cancer patients specifically, key decisions to think about in advance include: preferences about aggressive intervention (mechanical ventilation, CPR) in the event of cardiovascular collapse or respiratory failure; preferences about continuing versus stopping disease-directed therapy at various points; preferences about hospitalization versus home care in the final phase; and — for those who wish it — preferences about hospice enrollment and palliative sedation for refractory symptoms. These are decisions best made in unhurried conversations, not in the middle of a hospital crisis.

The list below is organized by category. Every phone number and website has been checked as current at the time of publication.

Disease-Specific Organizations

Survivorship and Late Effects

Caregiver and Community Support

Palliative Care and Hospice

Government and Coverage Resources

Clinical Trials

Legal Planning

Cancer rewards early action and planning across every phase — diagnosis, treatment, survivorship, and (for many) end-of-life care. The families who fare best move deliberately through the following sequence, adapted to the specific cancer type, stage, and personal preferences.

1Know Your Diagnosis Completely

At diagnosis, ask for and understand: the exact cancer type (histology), the stage (TNM system and overall stage grouping), the molecular subtype and any actionable mutations, the recommended treatment plan, the expected side effects, and the realistic prognosis. Every patient with metastatic or advanced-stage disease should have comprehensive molecular profiling — ask specifically whether next-generation sequencing has been ordered. Bring a family member or friend to every consultation to help take notes and ask questions.

2Get a Second Opinion for Complex or Serious Cancers

For advanced-stage cancers, rare cancers, cancers with complex treatment decisions, and any situation where the patient or family has doubts, a second opinion at a comprehensive cancer center (NCI- designated cancer center) is worth the effort. Second opinions confirm the diagnosis, validate or refine the treatment plan, and often identify clinical trials or specialized therapies not available locally. Most cancer centers offer expedited second-opinion pathways.

3Ask About Clinical Trials Early

Clinical trials are not last-resort options. For many cancers, the best available therapy is a trial-based regimen that will become standard of care in a few years. Ask specifically at diagnosis and at every treatment decision whether a trial is available and appropriate. Comprehensive cancer centers, NCI- designated centers, and many community oncology programs participate in trials. Use ClinicalTrials.gov, the NCI trial finder, and disease-specific advocacy organizations to identify options.

4Get a Geriatric Assessment if 65 or Older

Every adult 65 or older starting cancer treatment should receive a G-8 assessment or equivalent geriatric screening — a validated tool that identifies patients who benefit from a comprehensive geriatric assessment. Ask specifically whether geriatric oncology consultation is available. The tool guides treatment intensity decisions and identifies supportive interventions that can meaningfully change outcomes.

5Add Palliative Care Alongside Cancer Care

Palliative care is not the same as hospice and is not restricted to end-of-life. Multiple randomized trials show that early palliative care alongside standard cancer treatment improves quality of life, reduces depression, and in some studies extends survival. Ask for a palliative care consultation at diagnosis of any advanced cancer, when symptoms are not well controlled, or when treatment decisions become complex.

6Build the Caregiving Plan Before It Is Needed

Cancer treatment transforms family logistics. Identify who will drive to infusions and radiation, who will manage medications, who will monitor for side effects, and who will handle communication with the treatment team. Investigate transportation benefits through Medicare, Medicaid, and Medicare Advantage plans, and volunteer transportation programs run by cancer societies. Contact the local Area Agency on Aging through the Eldercare Locator for in-home aide services, meal delivery, and respite programs. Do this before the first treatment cycle, not after.

7Get a Written Survivorship Care Plan

At the end of primary cancer treatment, ask for a written survivorship care plan. It should list: the exact treatments received (including cumulative doses of anthracyclines or other cardiotoxic drugs, and any radiation fields), the specific late effects to watch for, the recommended surveillance schedule (imaging, blood work, tumor markers), and the primary care and specialist follow-up plan. This document is one of the most valuable single documents you will receive; keep it accessible and share copies with all treating clinicians.

8Address Late Effects Actively

Fatigue, cognitive changes, peripheral neuropathy, cardiac risk, bone loss, endocrine effects, sexual dysfunction, and psychological distress are all treatable, not inevitable. Do not accept survivorship symptoms as "just the way things are now." Cardio-oncology clinics, cognitive rehabilitation programs, cancer rehabilitation programs, sexual health services, and mental health support are all available at comprehensive cancer centers — many also through community-based programs. Ask specifically for referrals.

9Complete Advance Directives

Every adult with cancer should have (1) an advance directive naming preferences for aggressive interventions, (2) a durable power of attorney for health care naming a decision-maker, and (3) — separately — a durable power of attorney for finances. For cancer patients, key preferences to document include: intensity of treatment for recurrent or progressive disease, preferences about mechanical ventilation and CPR, preferences about hospitalization versus home care in the final phase, and — for those who wish it — preferences about hospice enrollment. State-specific forms are available free through the Family Caregiver Alliance and each state's bar association.

10Use Community Resources Proactively

Do not wait for crisis to call the American Cancer Society, CancerCare, disease-specific foundations, or the Eldercare Locator. Transportation assistance, home-delivered meals, in-home aide services, adult day programs, caregiver respite, patient navigation, and financial assistance are available through cancer-specific organizations and Area Agencies on Aging. Cancer center social workers and patient navigators — often underused — know the local landscape and can connect families to programs they didn't know existed.